📋 Immuneering Prepares To Share 12-Month Survival Data In Pancreatic Cancer Trial 완벽가이드
✨ Immuneering Prepares To Share 12-Month Survival Data In Pancreatic Cancer Trial
★ 56 전문 정보 ★
(RTTNews) – Immuneering Corporation (IMRX) announced that it will present updated 12-month overall survival data from its ongoing Phase 2a trial of Atebimetinib in combination with modified gemcitabine / nab-paclitaxel (mGnP) in first-line pancreatic cancer patients on January 7,
🎯 핵심 특징
✅ 고품질
검증된 정보만 제공
⚡ 빠른 업데이트
실시간 최신 정보
💎 상세 분석
전문가 수준 리뷰
📖 상세 정보
(RTTNews) – Immuneering Corporation (IMRX) announced that it will present updated 12-month overall survival data from its ongoing Phase 2a trial of Atebimetinib in combination with modified gemcitabine / nab-paclitaxel (mGnP) in first-line pancreatic cancer patients on January 7,